Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cusatuzumab Plus Azacitidine in Newly Diagnosed AML Not Eligible for Intensive Chemotherapy
2024-513283-26-00Phase 2Completed
- Sponsor
- OncoVerity
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of cusatuzumab and azacitidine in acute myeloid leukemia (AML), sponsored by OncoVerity. Primary endpoint: Complete response (CR) rate per ELN 2017. Started Jul 2024; status: completed.
02
Drugs
cusatuzumabazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-513283-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513283-26-00.